The chemokine signalling network drives inflammation and therefore many inflammatory diseases. However, it has evolved to be highly redundant to resist pathogenic shutdown, and so successful anti-chemokine therapeutics must target multiple chemokines simultaneously. During my DPhil, I will apply experimental and computational techniques to this ‘poly-pharmacological’ problem by characterising promiscuous therapeutics that can target multiple chemokines simultaneously and tackle chemokine-driven inflammatory disease.